Drugs acting on the immune system

Side Effects of Drugs Annual

Volumn 26, Issue , 2003, Pages 393-415

  Vial, Thierry ^a   Descotes, Jacques ^a   Screaton, Gavin ^a   Behrend, Matthias ^a   Ludwig, Corinna ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36148952482     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(03)80044-2     Document Type: Article

References (151)

1. Manns MP McHutchison JG Gordon SC Rustgi VK Shiffman M Reindollar R Goodman ZD Koury K Ling M Albrecht JK Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
2. Fruehauf S Steiger S Topaly J Ho AD Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia Ann. Hematol 80 2001 308 310
3. Karim A Ahmed S Khan A Steinberg H Mattana J Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection Am J Med Sci 322 2001 233 235
4. Suppl Kumar AS Russo MW Esposito S Borczuk A Jacobson I Brown M Brown RS Severe pulmonary toxicity of interferon and ribavirin therapy in chronic hepatitis C Am J Gastroenterol 96 2001 127
5. Patel M Ezzat W Pauw KL Lowsky R Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside Eur J Haematol 67 2001 318 321
6. Moulignier A Allo S Zittoun R Gout O Recombinant interferon-alpha-induced chorea and frontal subcortical dementia Neurology 58 2002 328 330
7. Borgia G Reynaud L Gentile I Cerini R Ciampi R Dello Russo M Piazza M Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C J Interferon Cytokine Res 21 2001 469 470
8. Weegink CJ Chamuleau RA Reesink HW Molenaar DS Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin J Gastroenterol 36 2001 723 724
9. Hejny C Sternberg P Lawson DH Greiner K Aaberg TM Retinopathy associated with high-dose interferon alfa-2b therapy Am J Ophthalmol 131 2001 782 787
10. Jain K Lam WC Waheeb S Thai Q Heathcote J Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin Br J Ophthalmol 85 2001 1171 1173
11. Saito H Ebinuma H Nagata H Inagaki Y Saito Y Wakabayashi K Takagi T Nakamura M Katsura H Oguchi Y Ishii H Interferon-associated retinopathy in a uniform regimen of natural interferot-alpha therapy for chronic hepatitis C Liver 21 2001 192 197
12. Castera L Zigante F Bastie A Buffet C Dhumeaux D Hardy P Incidence of interferon alfa-induced depression in patients with chronic hepatitis C Hepatology 35 2002 978 979
13. James CW Savini CJ Homicidal ideation secondary to interferon Ann Pharmacother 35 2001 962 963
14. Wesche B Jaeckel E Trautwein C Wedemeyer H Falorni A Frank H Von zur Muhlen A Manns MP Brabant G Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C Gut 48 2001 378 383
15. Eibl N Gschwantler M Ferenci P Eibl MM Weiss W Schernthaner G Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha Eur J Gastroenterol Hepatol 13 2001 295 298
16. Recasens M Aguilera E Ampurdanes S Sanchez Tapias JM Simo O Casamitjana R Conget I Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C Diabetic Med 18 2001 764 767
17. Carella C Mazziotti G Morisco F Manganella G Rotondi M Tuccillo C Sorvillo F Caporaso N Amato G Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment J Clin Endocrinol Metab 86 2001 1925 1929
18. Renou C Harafa A Bouabdallah R Demattei C Cummins C Rifflet H Muller P Ville E Bertrand J Benderitter T Halfon P Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary? Am J Gastroenterol 97 2002 1260 1263
19. Sagir A Wettstein M Heintges T Haussinger D Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C Dig Dis Sci 47 2002 562 563
20. Wilsson RA Interferon alfa-induced pernicious anemia in chronic hepatitis C infection J Clin Gastroenterol 33 2001 426 427
21. Carmona-Soria I Jimenez-Saenz M Gonzalez-Vilches J Herrerias-Gutierrez JM Development of lupic anticoagulant during combination therapy in a patient with chronic hepatitis C J Hepatol 34 2001 965 967
22. Iorio R Giannattasio A Vespere G Vegnente A LKM1 antibody and interferon therapy in children with chronic hepatitis C J Hepatol 35 2001 685 687
23. Bessis D Charron A Rouzier-Panis R Blatiere V Guilhou JJ Reynes J Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient Eur J Dermatol 12 2002 99 102
24. Marinho RT Johnson NW Fatela NM Serejo FS Gloria H Raimundo MO Velosa JF Ramalho FJ Moura MC Oropharyngeal pemphigus in a patient with chronic hepatitis C during interferon alpha-2a therapy Eur J Gastroenterol Hepatol 13 2001 869 872
25. Thomas R Stea B Radiation recall dermatitis from high-dose interferon alfa-2b J Clin Oncol 20 2002 355 357
26. Cogrel O Doutre MS Marliere V Beylot-Barry M Couzigou P Beylot C Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases Br J Dermatol 146 2002 320 324
27. Van Londen GJ Mascarenhas B Kirkwood JM Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI J Clin Oncol 19 2001 3794
28. Ozdag F Akar A Eroglu E Erbil H Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa J Dermatol Treat 12 2001 167 169
29. Ohmoto K Yamamoto S Angioedema after interferon therapy for chronic hepatitis C Am J Gastroenterol 96 2001 1311 1312
30. Beckman DB Mathisen TL Harris KE Boxer MB Grammer LC Hypersensitivity to IFN-alpha Allergy Eur J Allergy Clin Immunol 56 2001 806 807
31. Serrano J Prieto E Mazarbeitia F Roman A Llamas P Tomas JF Atypical chronic graftvesus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT Bone Marrow Transplant 27 2001 85 87
32. Hiratsuka M Minakami H Koshizuka S Sato I Administration of interferon-alpha during pregnancy: effects on fetus J Perinat Med 28 2000 372 376
33. Mubarak AA Kakil IR Awidi A Al-Homsi U Fawzi Z Kelta M Al-Hassan A Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature Am J Hematol 69 2002 115 118
34. Trotter JF Zygmunt AJ Conception and pregnancy during interferon-alpha therapy for chronic hepatitis C J Clin Gastroenterol 32 2001 76 78
35. Buckner JC Schomberg PJ McGinnis WL Cascino TL Scheithauer BW O'Fallon JR Morton RF Kuross SA Mailliard JA Hatfield AK Cole JT Steen PD Bernath AM A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma Cancer 92 2001 420 433
36. Nathan PD Gore ME Eisen TG Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma J Clin Oncol 20 2002 1429 1430
37. Sommer S Sablon JC Zaoui M Rozot P Hosni A Rétinopathie à l'interféron bêta au cours d'une sclérose en plaques J Fr Ophtalmol 24 2001 509 512
38. Heinzerling L Dummer R Burg G Schmid-Grendelmeier P Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patients Eur J Dermatol 12 2002 194 197
39. Durieu C Bayle-Lebey P Gadroy A Loche F Bazex J Hyperplasie endothéliale papillaire intravasculaire: multiples lésions apparues au cours d'un traitement par interféron bêta Ann Dermatol Venéreol 128 2001 1336 1338
40. Lunemann JD Kassim N Zschenderlein R Zipp F Schwarzenberger B Rhabdomyolysis during interferon-beta la treatment J Neurol Neurosurg Psychiatry 72 2002 274
41. Miwa H Furuya T Tanaka S Mizuno Y Neurosarcoidosis associated with interferon therapy Eur Neurol 45 2001 288 289
42. Suppl Sanberg-Wollheim M Outcome of pregnancy during treatment with interferon-beta-1a (Rebif) in patients with multiple sclerosis Neurology 58 2002 A445 A446
43. Watanabe M Kohge N Akagi S Uchida Y Sato S Kinoshita Y Congenital anomalies in a child born from a mother with interferon-treated chronic hepatitis B Am J Gastroenterol 96 2001 1668 1669
44. Bresnihan B The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis Semin Arthritis Rheum 30 2001 17 20
45. Schwartzentruber DJ Guidelines for the safe administration of high-dose interleukin-2 J Immunother 24 2001 287 293
46. Olsen E Duvic M Frankel A Kim Y Martin A Vonderheid E Jegasothy B Wood G Gordon M Heald P Oseroff A Pinter-Brown L Bowen G Kuzel T Fivenson D Foss F Glode M Molina A Knobler E Stewart S Cooper K Stevens S Craig F Reuben J Bacha P Nichols J Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376 388
47. Martin A Gutierrez E Muglia J McDonald CJ Guzzo C Gottlieb A Pappert A Garland WT Bagel J Bacha P A multicenter dose-escalation trial with denileukin diftitox in patients with severe psorasis J Am Acad Dermatol 45 2001 871 881
48. Bussel JB Mukherjee R Stone AJ A pilot study of rhuIL-11 treatment of refractory ITP Am J Hematol 66 2001 172 177
49. Bonig H Burdach S Gobel U Nurnberger W Growth factors and hemostasis: differential effects of GM-CSF and G-CSF on coagulation activation — laboratory and clinical evidence Ann Hematol 80 2001 525 530
50. Calderwood S Kilpatrick L Douglas SD Freedman M Smith-Whitley K Rolland M Kurtzberg J Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b Blood 97 2001 376 382
51. Nakayama T Kudo H Suzuki S Sassa S Mano Y Sakamoto S Splenomegaly induced by recombinant human granulocyte-colony stimulating factor in rats Life Sci 69 2001 1521 1529
52. Magen D Mandel H Berant M Ben-Izhak O Zelikovic I MPGN type I induced by granulocyte colony stimulating factor Pediatr Nephrol 17 2002 370 372
53. Mori T Sato N Watanabe R Okamoto S Ikeda Y Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor Bone Marrow Transplant 26 2000 239 240
54. Prendiville J Thiessen P Mallory SB Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colonystimulating factor (G-CSF) therapy Pediatr Dermatol 18 2001 417 421
55. Sekhar RV Culbert S Hoots WK Klein MJ Zietz H Vassilopoulou-Sellin R Severe osteopenia in a young boy with Kostmann's congenital neutropenia treated with granulocyte colony-stimulating factor: suggested therapeutic approach Pediatrics 108 2001 E54
56. Eleischmann R Iqbal I Nandeshwar P Quiceno A Safety and efficacy of disease-modifying antirheumatic agents: focus on the benefits and risks of etanercept Drug Saf 25 2002 173 197
57. Mohan N Edwards ET Cupps TR Oliverio PJ Sandberg G Crayton H Richert JR Siegel JN Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis Rheum 44 2001 2862 2869
58. Robinson WH Genovese MC Moreland LW Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44 2001 1977 1983
59. Allanore Y Bremont C Kahan A Menkes CJ Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept Clin Exp Rheumatol 19 2001 356 357
60. Stern A Buckley L Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy J Clin Rheumatol 7 2001 252 256
61. Zeltser R Valle L Tanck C Holyst MM Ritchlin C Gaspari AA Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein Arch Dermatol 137 2001 893 899
62. Bleumink GS Ter Borg EJ Ramselaar CG Stricker BHC Etanercept-induced subacute cutaneous lupus erythematosus Rheumatology 40 2001 1317 1319
63. De Bandt MJ Descamps V Meyer O Two cases of etanercept-induced systemic lupus erythematosus in patients with rheumatoid arthritis Ann Rheum Dis 60 2001 175
64. Misery L Perrot JL Gentil-Perret A Pallot-Prades B Cambazard F Alexandre C Dermatological complications of etanercept therapy for rheumatoid arthritis Br J Dermatol 146 2002 334 335
65. Shakoor N Michalska M Harris CA Block JA Drug-induced systemic lupus erythematosus associated with etanercept therapy Lancet 359 2002 579 580
66. Keane J Gershon S Wise RP Mirabile-Levens E Kasznica J Schwieterman WD Siegel JN Braun MM Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent New Engl J Med 345 2001 1098 1104
67. Baghai M Osmon DR Wolk DM Wold LE Haidukewych GJ Matteson EL Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept Mayo Clin Proc 76 2001 653 656
68. Myers A Clark J Foster H Tuberculosis and treatment with infliximab New Engl J Med 346 2002 623 626
69. Smith D Letendre S Viral pneumonia as a serious complication of etanercept therapy Ann Intern Med 136 2002 174
70. Takei S Groh D Bernstein B Shaham B Gallagher K Reiff A Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis J Rheumatol 28 2001 1677 1680
71. Willenbacher W Basara N Blau IW Fauser AA Kiehl MG Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab Br J Haematol 112 2001 820 823
72. Giles FJ Kantarjian HM Kornblau SM Thomas DA Garcia-Manero G Waddelow TA David CL Phan AT Colburn DE Rashid A Estey EH Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation Cancer 92 2001 406 413
73. Weisman MH What are the risks of biologic therapy in rheumatoid arthritis? An update on safety J Rheumatol Suppl 65 2002 33 38
74. Yee AM Pochapin MB Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy Ann Intern Med 135 2001 27 31
75. Braun J Brandt J Listing J Zink A Alten R Golder W Gromnica-Ihle E Kellner H Krause A Schneider M Sorensen H Zeidler H Thriene W Sieper J Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Lancet 359 2002 1187 1193
76. Marotte H Charrin JE Miossec P Inflaximab-induced aseptic meningitis Lancet 358 2001 1784
77. McCain ME Quinet RJ Davis WE Etanercept and infliximab associated with cutaneous vasculitis Rheumatology 41 2002 116 117
78. Puchner TC Kugathasan S Kelly KJ Binion DG Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction Inflammatory Bowel Dis 7 2001 34 37
79. O'Connor M Buchman A Marshall G Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease Dig Dis Sci 47 2002 1323 1325
80. Lankarani KB Mortality associated with infliximab J Clin Gastroenterol 33 2001 255 256
81. Riegert-Johnson DL Godfrey JA Myers JL Hubmayr RD Sandborn WJ Loftus EV Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion Inflammatory Bowel Dis 8 2002 186 191
82. Kugathasan S Levy MB Saeian K Vasilopoulos S Kim JP Prajapati D Emmons J Martinez A Kelly KJ Binion DG Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction Am J Gastroenterol 97 2002 1408 1414
83. Mayordomo M Marenco JL Gomez-Mateos J Rejon E Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment Scand J Rheumatol 31 2002 44 45
84. Nunez Martinez O Ripoll Noiseux C Carneros Martin^JA Gonzalez Lara V Gregorio Maranon HG Reactivation tuberculosis in a patient with anti-TNF-alpha treatment Am J Gastroenterol 96 2001 1665 1666
85. Roth S Delmont E Heudier P Kaphan R Cua E Castela J Verdier JM Chichmanian RM Fuzibet JG Anticorps anti-TNF alpha (infliximab) et tuberculose: à propos de 3 cas Rev Med Interne 23 2002 312 316
86. Rovere Querini P Vecellio M Sabbadini MG Ciboddo G Miliary tuberculosis after biological therapy for rheumatoid arthritis Rheumatology 41 2002 231
87. Wagner TE Huseby ES Huseby JS Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor Am J Med 112 2002 67 69
88. Kamath BM Mamula P Baldassano RN Markowitz JE Listeria meningitis after treatment with infliximab J Pediatr Gastroenterol Nutr 34 2002 410 412
89. Nakelchik M Mangino JE Reactivation of histoplasmosis after treatment with infliximab Am J Med 112 2002 78
90. Warris A Bjorneklett A Gaustad P Invasive pulmonary aspergillosis associated with infliximab therapy New Engl J Med 344 2001 1099 1100
91. Zhang Z Correa H Bégué RE Tuberculosis and treatment with infliximab New Engl J Med 246 2002 624
92. Busse W Corren J Lanier BQ McAlary M Fowler-Taylor A Cioppa GD Van As A Gupta N Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
93. Casale TB Condemi J LaForce C Nayak A Rowe M Watrous M McAlary M Fowler-Taylor A Racine A Gupta N Fick R DellaCioppa G Effect of omalizumab on symptoms of seasonal allergic rhinitis J Am Med Assoc 286 2001 2956 2967
94. Busse WW Anti-immunoglobulin E (omalizumab) therapy in allergic asthma Am J Respir Crit Care Med 164 2001 S12 S17
95. Boushey HA Experiences with monoclonal antibody therapy for allergic asthma J Allergy Clin Immunol 108 2001 S77 S83
96. Milgrom H Berger W Nayak A Gupta N Pollard S McAlary M Fowler-Taylor A Rohane P Treatment of childhood asthma with antiimmunoglobulin E antibody (omalizumab) Pediatrics 108 2001 E36
97. Casale TB Experience with monoclonal antibodies in allergic mediated disease: seasonal allergic rhinitis J Allergy Clin Immunol 108 Suppl 2 2001 S84 S88
98. Groothuis JR Simpson SJ Safety and tolerance of palivizumab administration in a large Northern hemisphere trial Pediatr Infect Dis J 20 2001 628 630
99. Byrd JC Waselenko JK Maneatis TJ Murphy T Ward FT Monahan BP Sipe MA Donegan S White CA Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance J Clin Oncol 17 1999 791 795
100. Davis TA White CA Grillo-Lopez AJ Velasquez WS Link B Maloney DG Dillman RO Williams ME Mohrbacher A Weaver R Dowden S Levy R Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab J Clin Oncol 17 1999 1851 1857
101. Van der Kolk LE Grillo-Lopez AJ Baars JW Hack CE Van Oers MH Complement activation plays a key role in the side-effects of rituximab treatment Br J Haematol 115 2001 807 811
102. Hagberg H Lundholm L Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia Br J Haematol 115 2001 609 611
103. Dervite I Hober D Morel P Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab New Engl J Med 344 2001 68 69
104. Sharma VR Fleming DR Slone SP Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab Blood 96 2000 1184 1186
105. Bermudez A Marco F Conde E Mazo E Recio M Zubizarreta A Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma Haematologica 85 2000 894 895
106. Ladetto M Zallio F Vallet S Ricca I Cuttica A Caracciolo D Corradini P Astolfi M Sametti S Volpato F Bondesan P Vitolo U Boccadoro M Pileri A Gianni AM Tarella C Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma Leukemia 15 2001 1941 1949
107. Seidman AD Fornier MN Esteva FJ Tan Valero V Currie V Gilewski T Theodoulou M Moynahan ME Moasser M Sklarin N Dickler M D'Andrea G Cristofanilli M Rivera E Hortobayi GN Norton L Hudis CA Weekly trastuzumab and placitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 19 2001 2587 2595
108. Slamon DJ Leyland-Jones B Shak S Fuchs H Paton V Bajanomde A Fleming T Eiermann W Wolter J Pegram M Baselga J Norton L Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 New Engl J Med 344 2001 783 792
109. Cuffari C Hunt S Bayless T Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease Gut 48 2001 642 646
110. Meggitt SJ Reynolds NJ Azathioprine for atopic dermatitis Clin Exp Dermatol 26 2001 369 375
111. Marbet U Schimid I Severe life-threatening diarrhea caused by azathioprine but not by 6-mercaptopurine Digestion 63 2001 139 142
112. Kappers-Klune MC Van't Veer MB Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy Br J Haematol 114 2001 121 125
113. Cortes J O'Brien S Loscertales J Kantarjian H Giles F Thomas D Koller C Keating M Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia Cancer 92 2001 2016 2022
114. Rosencrantz R Moon A Raynes H Spivak W Cyclosporine-induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors Am J Gastroenterol 96 2001 2778 2782
115. Massy ZA Hyperlipidemia and cardiovascular disease after organ transplantation Transplantation 72 Suppl 6 2001 S13 S15
116. Trimarchi H Freixas E Rabinovich O Schropp J Pereyra H Bullorsky E Cyclosporineassociated thrombotic microangiopathy during daclizumab induction: a suggested therapeutic approach Nephron 87 2001 361 364
117. Albengres E Le Louet H D'Athis P Tillement JP S15176 and S16950 interaction with cyclosporin A antiproliferative effect on cultured human lymphocytes Fundam Clin Pharmacol 15 2001 41 46
118. Monegal A Navasa M Guanabens N Peris P Pons F Martinez de Osaba MJ Rimola A Rodes J Munoz-Gomez J Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A Calcif Tissue Int 68 2001 83 86
119. Ichimaru N Takahara S Kokado Y Wang JD Hatori M Kameoka H Inoue T Okuyama A Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus Atherosclerosis 158 2001 417 423
120. Barone GW Gurley BJ Ketel BL Abul-Ezz SR Herbal supplements: a potential for drug interactions in transplant recipients Transplantation 71 2001 239 241
121. Malingre MM Beijnen JH Rosing H Koopman FJ Van Tellingen O Duchin K Ten Bokkel-Huinink WW Swart M Lieverst J Schellens JH A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A Cancer Chemother Pharmacol 47 2001 347 354
122. Bar Oz B Hackman R Einarson T Koren G Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis Transplantation 71 2001 1051 1055
123. Weinstein SP Orel SG Collazzo L Conant EF Lawton TJ Czerniecki B Cyclosporin A-induced fibroadenomas of the breast: report of five cases Radiology 220 2001 465 468
124. Baildam Ad Higgins RM Hurley E Furlong A Walls J Venning MC Ackrill P Mansel RE Cyclosporin A and multiple fibroadenomas of the breast Br J Surg 83 1996 1755 1757
125. Foxwell BM Woerly G Husi H Mackie A Quesniaux VF Hiestand PC Wenger RM Ryffel B Identification of several cyclosporine binding proteins in lymphoid and non-lymphoid cells in vivo Biochim Biophys Acta 1138 1992 115 121
126. Lopez-Calderon A Soto L Villanua MA Vidarte L Martin AI The effect of cyclosporine administration on growth hormone release and serum concentrations of insulin-like growth factor-I in male rats Life Sci 64 1999 1473 1483
127. Russell DH Kibler R Matrisian L Larson DF Poulos B Magun BE Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine J Immunol 134 1985 3027 3031
128. Larson DF Cyclosporin. Mechanism of action: antagonism of the prolactin receptor Prog Allergy 38 1986 222 238
129. Kenney LB Laufer MR Grant FD Grier H Diller L High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood Cancer 91 2001 613 621
130. Coutinho HM Groothoff JW Offringa M Gruppen MP Heymans HS De novo malignancy after paediatric renal replacement therapy Arch Dis Child 85 2001 478 483
131. Kovarik JM Kahan BD Kaplan B Lorber M Winkler M Rouilly M Gerbeau C Cambon N Boger R Rordorf C Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine Clin Pharmacol Ther 69 2001 48 56
132. Jover JA Hernandez-Garcia C Morado IC Vargas E Banares A Fernandez-Gutierrez B Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial Ann Intern Med 134 2001 106 114
133. Stewart M Malkovska V Krishnan J Lessin L Barth W Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab Ann Rheum Dis 60 2001 892 893
134. Stewart SF Hudson M Talbot D Manas D Day CP Mycophenolate mofetil monotherapy in liver transplantation Lancet 357 2001 609 610
135. Schlitt HJ Barkmann A Boker KH Schmidt HH Emmanouilidis N Rosenau J Bahr MJ Tusch G Manns MP Nashan B Klempnauer J Replacement of calcineurin inhibitors with myocphenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study Lancet 357 2001 587 591
136. Staskewitz A Kirste G Tonshoff B Weber LT Boswald M Burghard R Helmchen U Brandis M Zimmerhackl LB Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment German Pediatric Renal Transplantation Study Group. Transplantation 71 2001 638 644
137. Grundmann-Kollmann M Podda M Ochsendorf F Boehncke WH Kaufmann R Zollner TM Mycophenolate mofetil is effective in the treatment of atopic dermatitis Arch Dermatol 137 2001 870 873
138. Neyts J Andrei G De Clercq E The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo Antimicrob Agents Chemother 42 1998 216 222
139. Pergola PE Kancharla A Riley DJ Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone Transplantation 71 2001 994 997
140. Bottiger Y Sawe J Brattstrom C Tollemar J Burke JT Hass G Zimmerman JJ Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers Clin Pharmacol Ther 69 2001 32 40
141. Parvex P Pinsk M Bell LE O'Gorman AM Patenaude YG Gupta IR Reversible encephalopathy associated with tacrolimus in pediatric renal, transplants Pediatr Nephrol 16 2001 537 542
142. Furukawa M Terae S Chu BC Kaneko K Kamada H Miyasaka K MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging Neuroradiology 43 2001 615 621
143. Tze WJ Tai J Murase N Tzakis A Starzl TE Effect of FK 506 on glucose metabolism and insulin secretion in normal rats Transplant Proc 23 1991 3158 3160
144. Paolillo JA Boyle GJ Law YM Miller SA Lawrence K Wagner K Pigula FA Griffith BP Webber SA Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression Transplantation 71 2001 252 256
145. Jain A Kashyap R Marsh W Rohal S Khanna A Fung JJ Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus Transplantation 71 2001 1102 1106
146. Kang S Lucky AW Pariser D Lawrence I Hanifin JM Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children J Am Acad Dermatol 44 Suppl 1 2001 S58 S64
147. Soter NA Fleischer AB Jr Webster GF Monroe E Lawrence I Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part II, safety J Am Acad Dermatol 44 Suppl 1 2001 S39 S46
148. Paller A Eichenfield LF Leung DY Stewart D Appell M A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients J Am Acad Dermatol 44 Suppl 1 2001 S47 S57
149. Blackhall FH Ranson M Radford JA Hancock BW Soukop M McGown AT Robbins A Halbert G Jayson GC A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma Br J Cancer 84 2001 465 469
150. Coutts SM Plunkett ML Iverson GM Barstad PA Berner CM Pharmacological intervention in antibody mediated disease Lupus 5 1996 158 159
151. Furie RA Cash JM Cronin ME Katz RS Weisman MH Aranow C Liebling MR Hudson NP Berner CM Coutts S de Haan HA Treatment of systemic lupus erythematosus with LJP 394 J Rheumatol 28 2001 257 265